Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary?
Renou
C
C
Harafa
A
A
Bouabdallah
R
R
Dematteï
C
C
Cummins
C
C
Rifflet
H
H
Muller
P
P
Ville
E
E
Bertrand
J
J
Benderitter
T
T
Halfon
P
P
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced*; D011994:Recombinant Proteins
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins